ERELZI
Drug
Sandoz Inc.
Total Payments
$248,093
Transactions
94
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $45,505 | 24 | 4 |
| 2018 | $8,234 | 7 | 0 |
| 2017 | $194,354 | 63 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $230,287 | 81 | 92.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,736 | 4 | 5.5% |
| Travel and Lodging | $2,509 | 5 | 1.0% |
| Consulting Fee | $1,300 | 1 | 0.5% |
| Food and Beverage | $260.37 | 3 | 0.1% |
Payments by Type
Research
$230,287
81 transactions
General
$17,806
13 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PHASE III STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY & IMMUNOGENICITY OF GP2015 AND ENBREL? (EU AUTHORIZED) IN PATIENTS WITH MODERATE TO SEVERE, ACTIVE RHEUMATOID ARTHRITIS | Sandoz Inc. | $182,031 | 1 |
| A RANDOMIZED DOUBLE-BLIND PARALLEL-GROUP PHASE III STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY & IMMUNOGENICITY OF GP2015 AND ENBREL? (EU AUTHORIZED) IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS | Sandoz Inc. | $28,999 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PHASE III STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY AND IMMUNOGENICITY OF GP2015 AND ENBREL (EU AUTHORIZED) IN PATIENTS WITH MODERATE TO SEVERE, ACTIVE RHEUMATOID ARTHRITIS | Sandoz Inc. | $16,757 | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PHASE III STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY & IMMUNOGENICITY OF GP2015 AND ENBREL EU AUTHORIZED) IN PATIENTS WITH MODERATE TO SEVERE, ACTIVE RHEUMATOID ARTHRITIS | Sandoz Inc. | $2,500 | 0 |
Top Doctors Receiving Payments for ERELZI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Albuquerque, NM | $225,735 | 79 |
| , MD | Internal Medicine | Colleyville, TX | $5,924 | 6 |
| , M.D | Hematology & Oncology | Rock Hill, SC | $5,696 | 3 |
| , M.D | Rheumatology | Portola Valley, CA | $4,886 | 3 |
| Nathan Wei | — | Frederick, MD | $4,552 | 2 |
| David Rubin | Gastroenterology | Burr Ridge, IL | $1,300 | 1 |
Ad
Manufacturing Companies
- Sandoz Inc. $248,093
Product Information
- Type Drug
- Total Payments $248,093
- Total Doctors 5
- Transactions 94
About ERELZI
ERELZI is a drug associated with $248,093 in payments to 5 healthcare providers, recorded across 94 transactions in the CMS Open Payments database. The primary manufacturer is Sandoz Inc..
Payment data is available from 2017 to 2019. In 2019, $45,505 was paid across 24 transactions to 4 doctors.
The most common payment nature for ERELZI is "Unspecified" ($230,287, 92.8% of total).
ERELZI is associated with 4 research studies, including "A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PHASE III STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY & IMMUNOGENICITY OF GP2015 AND ENBREL? (EU AUTHORIZED) IN PATIENTS WITH MODERATE TO SEVERE, ACTIVE RHEUMATOID ARTHRITIS" ($182,031).